Occurrence and characterization of everolimus adverse events during first and subsequent cycles in the treatment of metastatic breast cancer

[1] Miller TW(2010)Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer J Clin Invest 7 2406-2413

[2] Hennessy BT(2007)Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling Ann Oncol 8 1323-1328

[3] Gonzalez-Angulo AM(2005)Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 14 5319-5328

[4] Beeram M(2004)Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity Clin Cancer Res 23 8059-8067

[5] Tan QT(2008)mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels Cancer Sci 10 1992-2003

[6] Tekmal RR(2012)Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer Breast Cancer Res 5 R138-529

[7] Russell D(2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 6 520-884

[8] Middleton A(2013)Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis Adv Ther 10 870-815

[9] DeGraffenried LA(2014)Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 Ann Oncol 25 808-E89

[10] Boulay A(2011)Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors Clin J Oncol Nurs 5 E83-315

[1] Miller TW(2010)Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer J Clin Invest 7 2406-2413

[2] Hennessy BT(2007)Akt-induced endocrine therapy resistance is reversed by inhibition of mTOR signaling Ann Oncol 8 1323-1328

[3] Gonzalez-Angulo AM(2005)Dual inhibition of mTOR and estrogen receptor signaling in vitro induces cell death in models of breast cancer Clin Cancer Res 14 5319-5328

[4] Beeram M(2004)Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt activity Clin Cancer Res 23 8059-8067

[5] Tan QT(2008)mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels Cancer Sci 10 1992-2003

[6] Tekmal RR(2012)Aberrations in translational regulation are associated with poor prognosis in hormone receptor-positive breast cancer Breast Cancer Res 5 R138-529

[7] Russell D(2012)Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer N Engl J Med 6 520-884

[8] Middleton A(2013)Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis Adv Ther 10 870-815

[9] DeGraffenried LA(2014)Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2 Ann Oncol 25 808-E89

[10] Boulay A(2011)Managing stomatitis in patients treated with mammalian target of rapamycin inhibitors Clin J Oncol Nurs 5 E83-315